Cilostazol novel neuroprotective mechanism against rotenone-induced Parkinson's disease in rats: Correlation between Nrf2 and HMGB1/TLR4/PI3K/Akt/mTOR signaling
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.109986 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Rehab M El-Sayed und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Sinai University, El-Arish, Egypt. Hauptthemen laut MEDLINE: Parkinson Disease, HMGB1 Protein, Neuroprotective Agents. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 79 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Sinai University, El-Arish, Egypt.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Sinai University, El-Arish, Egypt. Electronic address: ahmed.abdelaziz@su.edu.eg.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Zitieren
APA
El-Sayed, R. M., Abdelaziz, A. M., Zaki, H. F., & Abdel Rasheed, N. O. (2023). Cilostazol novel neuroprotective mechanism against rotenone-induced Parkinson's disease in rats: Correlation between Nrf2 and HMGB1/TLR4/PI3K/Akt/mTOR signaling. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.109986
Vancouver
El-Sayed RM, Abdelaziz AM, Zaki HF, Abdel Rasheed NO. Cilostazol novel neuroprotective mechanism against rotenone-induced Parkinson's disease in rats: Correlation between Nrf2 and HMGB1/TLR4/PI3K/Akt/mTOR signaling. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.109986
BibTeX
@article{ElSayed2023,
author = {El-Sayed, Rehab M and Abdelaziz, Ahmed M and Zaki, Hala F and Abdel Rasheed, Nora O},
title = {Cilostazol novel neuroprotective mechanism against rotenone-induced Parkinson's disease in rats: Correlation between Nrf2 and HMGB1/TLR4/PI3K/Akt/mTOR signaling},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.109986}
}
EUVIMED